develop

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event

Recent clinical studies support the development of DG041 as aneffective anti-platelet that does not increase bleeding risk REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced progress in the development ofDG041, the company's Phase II developmental compound for theprevention of arterial thrombosis. The results of the Phase IIa andclinical pharmacolog...

Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced CellTechnology, Inc. (OTCBB: ACTC) has successfully produced a humanembryonic stem cell (hESC) line without destroying an embryo at itslab in Worcester, Massachusetts. This development was announced byRobert Lanza, M.D., V.P. of Research and Scientific Development ofAdvanced Cell Technology (ACT) on Tuesday at the fifth annualmeeting...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- AnadysPharmaceuticals, Inc. , a biopharmaceutical company committed tothe discovery, development and commercialization of novel medicinesfor the treatment of hepatitis and cancer, announced today that ithas nominated ANA598 as a candidate for clinical development as anorally-administered direct antiviral for the treatment of chronichepat...

Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting

MONTREAL, QUEBEC--(CCNMatthews - June 14, 2007) - AmbriliaBiopharma Inc. (TSX:AMB), a biopharmaceutical company developingnovel small molecules and peptides to treat infectious diseases andcancer, held its Annual General and Special Meeting today, duringwhich the data reported yesterday on its novel series of HIVintegrase inhibitors and recent developments were highlighted. Themeeting wa...

Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-FiteBioPharma (TASE:CFBI), a biotechnology company traded on the TelAviv Stock Exchange Exchange, proceeds with the development of itsthird drug CF502; this is in addition to CF101, which is currentlyin clinical trials and CF102, which is in preclinical phases. Thisweekend Can-Fite will present at the EUALR annual congress ofrheumato...

CuraGen Presents Update on Clinical Development Program for Belinostat

- Clinical activity reported against CTCL, PTCL and Ovarian Cancers- BRANFORD, Conn., June 12, 2007 /PRNewswire-FirstCall/ -- CuraGenCorporation , a clinical-stage biopharmaceutical company focused ononcology, presented today an update on the clinical developmentprogram for belinostat, a histone deacetylase (HDAC) inhibitor, andreported updated results suggesting clinical activity of beli...

Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - PanacosPharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology companydedicated to developing the next generation of antiviraltherapeutic products, today announced the results of a new studyindicating that HIV resistant to Protease Inhibitors (PI) may havereduced potential for the development of resistance to the HIVmaturation inhibitor bevirim...

New Critical Path Report Highlights Research Needed to Foster Generic Drug Development

ROCKVILLE, Md., May 2, 2007-The U.S. Food and DrugAdministration (FDA) today issued the "<a target="_blank" href="http://www.fda.gov/oc/initiatives/criticalpath/reports/generic.html">CriticalPath Opportunities for Generic Drugs " report identifying manyof the unanswered scientific questions that impede the developmentof generic versions of commonly used drugs. The report is part...

Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

VIENNA, Austria, May 18, 2007 – Intercell AG (VSE,“ICLL”) has been informed by its strategic partnerMerck & Co., Inc. on the results of a Phase I study involvingin total over 120 adult healthy volunteers comparing safety andimmunogenicity of different doses of the Staphylococcus aureusvaccine. The Staphylococcus aureus vaccine is based on a conserved prote...

DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECTCorporation announced today that Voyager Pharmaceutical hasprovided its shareholders with an update on its truncated Phase 3clinical trial for Memryte, an investigational drug for thetreatment of Alzheimer's disease. Voyager has informed itsshareholders that they have observed positive outcome trends amongwomen, but no posit...

Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference

NEWTON, Mass.--(BUSINESS WIRE)--May 17, 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a developer of novel, first-in-class carbohydratecompounds today announced that Eliezer Zomer, Ph.D., Executive VicePresident, Product Development and Manufacturing will present,"Pharmacokinetic Translational Study in Advanced Solid Tumors of5-FU with an Admixture of a Galactomannan Derivative," at theInter...

Apollo develops needle-free topical vaccine

SYDNEY, April 30, 2007-Australian bio-discovery company ApolloLife Sciences has released results of preliminary trials of itspatented needle-free vaccine technology, which delivers tetanusvaccine transdermally (through the skin) without the need for aninjection. According to Apollo CEO John Priest, the research points the wayto the possibility that flu injections may soon be a thin...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 19, 2007 - IgG1 monoclonalantibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL)were the focus of 44 total presentations at the recently concluded98th Annual Meeting of the American Association for Cancer Research(AACR), including seven oral presentations and 37 posters. Important ERBITUX(R) (cetuximab) clinical data were the focus oftwo back-to...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - AlnylamPharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuticscompany, announced today at the American Association for CancerResearch (AACR) 2007 Annual Meeting that it will advance asystemically delivered RNAi therapeutic, ALN-VSP01, for thetreatment of liver cancer and potentially other solid tumors as anew development program. A...

Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR

-IND filing expected by end of 2007- EDMONTON, April 16, 2007 /PRNewswire-FirstCall/ - Biomira Inc.today announced that it has selected PX-866 as its next clinicaldevelopment candidate. PX-866 is an inhibitor of thephosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, animportant survival signaling pathway that is activated in manytypes of human cancer, including glioblastoma. Pre...

Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatallyflawed CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findingspresented yesterday at a National Autism Association meetingbolster claims that vaccines may play a role in the development ofautism spectrum disorders. David Ayoub, MD presented datasuggesting a correlation between mercury- containing vaccines andrates of...